Effectiveness of vaccines against infection: living systematic review
covid1.substack.com
Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021 We used an internal COVID-19 literature database constructed by the RKI library to search for relevant studies. This database covers PubMed, Embase (including Medline) and the preprint servers ArRvix, BioRxiv, ChemRxiv, MedRxiv, Preprints.org, ResearchSquare and Social Science Research Network (SSRN). We identified and screened a total of 4,870 entries. After screening 204 full-text articles, 30 studies were included. Two studies were RCTs, 19 studies had a cohort design and five were case–control studies, including two with test-negative design. One-dose efficacy/effectiveness was investigated in 24 studies (Table 1) and estimates ranged from 16.9% to 91.2%, with the majority of estimates ranging between 60% and 70%. In 17 of 26 studies, VE was reported after the second dose. Estimates ranged between 61.7% and 98.6%. These interim results of a living systematic review show that after completed course the EMA-approved COVID-19 vaccines have a VE of 80% to 90% in preventing SARS-CoV2 infections, including asymptomatic ones. At the time point of data cut for this interim analysis, only limited information was available on VOCs other than Alpha. Meanwhile, some studies have been published indicating reduced effectiveness against infections with VOC Delta for Comirnaty and Vaxzevria.
Effectiveness of vaccines against infection: living systematic review
Effectiveness of vaccines against infection…
Effectiveness of vaccines against infection: living systematic review
Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021 We used an internal COVID-19 literature database constructed by the RKI library to search for relevant studies. This database covers PubMed, Embase (including Medline) and the preprint servers ArRvix, BioRxiv, ChemRxiv, MedRxiv, Preprints.org, ResearchSquare and Social Science Research Network (SSRN). We identified and screened a total of 4,870 entries. After screening 204 full-text articles, 30 studies were included. Two studies were RCTs, 19 studies had a cohort design and five were case–control studies, including two with test-negative design. One-dose efficacy/effectiveness was investigated in 24 studies (Table 1) and estimates ranged from 16.9% to 91.2%, with the majority of estimates ranging between 60% and 70%. In 17 of 26 studies, VE was reported after the second dose. Estimates ranged between 61.7% and 98.6%. These interim results of a living systematic review show that after completed course the EMA-approved COVID-19 vaccines have a VE of 80% to 90% in preventing SARS-CoV2 infections, including asymptomatic ones. At the time point of data cut for this interim analysis, only limited information was available on VOCs other than Alpha. Meanwhile, some studies have been published indicating reduced effectiveness against infections with VOC Delta for Comirnaty and Vaxzevria.